Citations

Mayo Clinic

Showing 10 of 108602 citations.

P065 Post COVID-19 Syndrome in patients with autoimmune rheumatic diseases: Results from the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study
Gupta, Latika, Naveen, R, Jagtap, Kshitij , Nikiphorou, Elena , Parodis, Ioannis , Kuwana, Masataka , Group, COVAD Study, Parodis, Ioannis , Jagtap, Kshitij , Sen, Parikshit , Joshi, Mrudula , Saha, Sreoshy , Agarwal, Vishwesh , Distler, Oliver , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Milchert, Marcin , Makol, Ashima , Pauling, John D , Wincup, Chris , Lilleker, James B , Nune, Arvind , Day, Jessica , Chinoy, Hector , Group, COVAD Study, Agarwal, Vikas , Aggarwal, Rohit

Rheumatology | April 24, 2023 | Volume: 62 | Issue: Supplement_2 | Pages: No page available

10.1093/rheumatology/kead104.106 Get It

Abstract Background/Aims Post COVID-19 syndrome (PCS) is an emerging cause of morbidity and poor quality of life in COVID-19 survivors. We aimed to assess the prevalence, risk factors, outcomes, and association with disease flares of PCS in patients with autoimmune rheumatic diseases (AIRDs) and non-rheumatic autoimmune diseases (nrAIDs), both vulnerable groups understudied in the current literature using data from the 2nd COVID-19 Vaccination in Autoimmune Diseases (COVAD) global multicentre patient self-reported e-survey. Methods The survey was circulated from February to July 2022 by the international COVAD Study Group (157 collaborators from 106 countries), and demographics, comorbidities, AIRD/nrAID status, COVID-19 history, vaccination details, and PROMIS physical and mental function were recorded. PCS was defined as symptom resolution time >90 days following acute COVID-19. Predictors of PCS were analysed using regression models for the different groups. Results 7666 total respondents completed the survey. Of these, 2650 respondents with complete responses had positive COVID-19 infection, and 1677 (45.0% AIRDs, 12.5% nrAIDs, 42.5% HCs) completed the survey >90 days post acute COVID-19. Of these, 136 (8.1%) had PCS. Prevalence of PCS was higher in AIRDs (10.8%) than healthy controls HCs (5.3%) (OR: 2.1; 95%CI: 1.4-3.1, p = 0.002). Across the entire cohort, a higher risk of PCS was seen in women (OR: 2.9; 95%CI: 1.1-7.7, p = 0.037), patients with long duration of AIRDs/nrAIDs (OR 1.01; 95%CI: 1.0-1.02, p = 0.016), those with comorbidities (OR: 2.8; 95%CI: 1.4-5.7, p = 0.005), and patients requiring oxygen supplementation for severe acute COVID-19 (OR: 3.8; 95%CI: 1.1-13.6, p = 0.039). Among patients with AIRDs, comorbidities (OR 2.0; 95%CI: 1.08-3.6, p = 0.026), and advanced treatment (OR: 1.9; 95%CI: 1.08-3.3, p = 0.024), or intensive care (OR: 3.8; 95%CI: 1.01-14.4, p = 0.047) for severe COVID-19 were risk factors for PCS. Notably, patients who developed PCS had poorer PROMIS global physical [15 (12-17) vs 12 (9-15)] and mental health [14 (11-16) vs 11 (8-14)] scores than those without PCS. Conclusion Individuals with AIRDs have a greater risk of PCS than HCs. Associated comorbid conditions, and advanced treatment or intensive care unit admission for severe COVID-19 confer a higher risk of PCS. It is imperative to identify risk factors for PCS for immediate multidisciplinary management in anticipation of poor physical and mental health. Disclosure L. Gupta: None. P. Sen: None. N. R: None. M. Joshi: None. S. Saha: None. K. Jagtap: None. V. Agarwal: None. O. Distler: Consultancies; Abbvie, Acceleron, Alcimed, Amgen, AnaMar, Arxx, Baecon, Blade, Bayer, Boehringer Ingelheim, ChemomAb, Corbus, CSL Behring, Galapagos, Glenmark, GSK, Horizon (Curzion), Inventiva, iQvia, Kymera, Lupin, Medac, Medscape, Mitsubishi Tanabe, Novartis, Roche, Roivant, Sanofi, Serodapharm, Topadur and UCB. E. Nikiphorou: Honoraria; Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, and Lilly. Grants/research support; Pfizer and Lilly. A. Tan: Honoraria; Abbvie, Gilead, Janssen, Lilly, Novartis, Pfizer, and UCB. S. Shinjo: None. N. Ziade: Honoraria; Pfizer, Roche, Abbvie, Eli Lilly, NewBridge, Sanofi-Aventis, Boehringer Ingelheim, Janssen, and Pierre Fabre. M. Milchert: None. I. Parodis: Honoraria; Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG. M. Kuwana: None. A. Makol: None. J.D. Pauling: None. C. Wincup: None. J. Lilleker: Honoraria; Sanofi Genzyme, Roche, and Biogen. A. Nune: None. J. Day: Grants/research support; CSL Limited. H. Chinoy: Consultancies; Novartis, Eli Lilly, Orphazyme, Astra Zeneca. Honoraria; UCB, and Biogen. Grants/research support; Eli Lilly and UCB. V. Agarwal: None. R. Aggarwal: Consultancies; Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Abbvie, Janssen, Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, and Roivant.
Evaluating expertise in forensic anthropology
Passalacqua, Nicholas V. , Tersigni‐Tarrant, MariaTeresa A., Langley, Natalie R. , Pilloud, Marin A

Journal of Forensic Sciences | April 24, 2023 | Volume: 68 | Issue: 4 | Pages: 1111-1120

10.1111/1556-4029.15262 | PMID 37092592 Get It

AbstractThe medicolegal system relies on the ability of experts and non‐experts alike to make judgments about expertise and use those judgments to reach consequential decisions. Given the lack of standard criteria, mandatory certification, or licensure for establishing expertise required to practice forensic anthropology and testify as an expert witness, we sought to understand how individuals assess and identify expertise in forensic anthropology by using a social science tool called the Imitation Game. This tool assesses immersion in a specific area of study via discourse, with the premise that some individuals lacking expertise themselves imitate or attempt to pass as experts. For this project we recruited volunteers with varying expertise in forensic anthropology to participate in interviews which asked questions about the practice and structure of the discipline. Those interviews were transcribed, anonymized, and evaluated by other recruited individuals with varying expertise in forensic anthropology. Results found that judges who were experts in forensic anthropology performed better than non‐expert judges in determining who was not an expert in forensic anthropology based on their anonymized responses; however, nearly half of the non‐experts were still able to pass as experts in forensic anthropology. The difficulties in assessing expertise based on discourse interactions demonstrates the value and need for well‐defined credentials and mandatory certification to practice forensic anthropology. This study demonstrates that accurately identifying expertise in forensic anthropology may be challenging for both experts and non‐experts, especially when relying solely on interactional expertise rather than formal assessments of competency which directly elucidate contributory expertise.
Senolytic therapy to modulate the progression of Alzheimer’s Disease (SToMP-AD) – Outcomes from the first clinical trial of senolytic therapy for Alzheimer's disease
Orr, Miranda E. , Gonzales, Mitzi M. , Garbarino, Valentina R. , Kautz, Tiffany F. , Palavicini, Juan Pablo , Lopez‐Cruzan, Marisa , Dehkordi, Shiva Kazempour , Mathews, Julia, Zhang, Bin , Franklin, Crystal , Craft, Suzanne , Petersen, Ronald C. , Kirkland, James L. , Salardini, Arash , Musi, Nicolas , Palavicini, Juan Pablo , Lopez-Cruzan, Marisa , Dehkordi, Shiva Kazempour , Xu, Peng , Petersen, Ronald C , Tchkonia, T , Kirkland, James L , Orr, Miranda E , Gonzales, Mitzi , Zare, Habil , Habes, Mohamad , Tchkonia, Tamar , Seshadri, Sudha

No container title available | April 24, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2809973/v1 | PMID 37162971 Get It

Abstract Cellular senescence has been identified as a pathological mechanism linked to tau and amyloid beta (Aβ) accumulation in mouse models of Alzheimer's disease (AD). Clearance of senescent cells using the senolytic compounds dasatinib (D) and quercetin (Q) reduced neuropathological burden and improved clinically relevant outcomes in the mice. Herein, we conducted a vanguard open-label clinical trial of senolytic therapy for AD with the primary aim of evaluating central nervous system (CNS) penetrance, as well as exploratory data collection relevant to safety, feasibility, and efficacy. Participants with early-stage symptomatic AD were enrolled in an open-label, 12-week pilot study of intermittent orally-delivered D+Q. CNS penetrance was assessed by evaluating drug levels in cerebrospinal fluid (CSF) using high performance liquid chromatography with tandem mass spectrometry. Safety was continuously monitored with adverse event reporting, vitals, and laboratory work. Cognition, neuroimaging, and plasma and CSF biomarkers were assessed at baseline and post-treatment. Five participants (mean age: 76±5 years; 40% female) completed the trial. The treatment increased D and Q levels in the blood of all participants ranging from 12.7 to 73.5 ng/ml for D and 3.29-26.30 ng/ml for Q. D levels were detected in the CSF of four participants ranging from 0.281 to 0.536 ng/ml (t(4)=3.123, p=0.035); Q was not detected. Treatment was well-tolerated with no early discontinuation and six mild to moderate adverse events occurring across the study. Cognitive and neuroimaging endpoints did not significantly differ from baseline to post-treatment. CNS levels of IL-6 and GFAP increased from baseline to post-treatment (t(4)=3.913, p=008 and t(4)=3.354, p=0.028, respectively) concomitant with decreased levels of several cytokines and chemokines associated with senescence, and a trend toward higher levels of Aβ42 (t(4)=-2.338, p=0.079). Collectively the data indicate the CNS penetrance of D and provide preliminary support for the safety, tolerability, and feasibility of the intervention and suggest that astrocytes and Aβ may be particularly responsive to the treatment. While early results are promising, fully powered, placebo-controlled studies are needed to evaluate the potential of AD modification with the novel approach of targeting cellular senescence.
COVID-19 and Sleep Disturbances: A Literature Review of Clinical Evidence
Shaik, Likhita, Boike, Sydney , Ramar, Kannan , Subramanian, Shyam, Surani, Salim , Surani, Salim , Boike, Sydney

Medicina | April 24, 2023 | Volume: 59 | Issue: 5 | Pages: 818

10.3390/medicina59050818 | PMID 37241050 Get It

The need for adequate good quality sleep to optimally function is well known. Over years, various physical, psychological, biological, and social factors have been investigated to understand their impact on sleep. However, understanding the etiological processes that are involved in causing sleep disturbances (SD) as impacted by stressful phases such as pandemics has not been well studied. Many such etiological and management strategies have surfaced during the latest “coronavirus disease of 2019 (COVID-19) pandemic. The occurrence of these SD in the infected and uninfected individuals poses a need to investigate factors linked to such occurrence during this phase. Some of such factors include stressful practices such as social distancing, masking, vaccines, and medications availability, changes in routines, and lifestyles. As the status of infection improved, a collective term for all the prolonged effects of COVID-19 after the resolution of the primary infection called the post-COVID-19 syndrome (PCS) surfaced. Apart from impacting sleep during the infectious phase, the aftereffects of this virus left an even greater impact during the PCS. Various mechanisms have been hypothesized to be linked to such SD during the PCS, but the available data are inconclusive. Further, the varied patterns of incidence of these SDs differed by many factors, such as age, gender, and geographical location, making clinical management even more challenging. This review elucidates the impact of coronavirus 2 (SARS-CoV-2) (COVID) disease on sleep health during the various phases of the COVID-19 pandemic. We also investigate different causal relationships, management strategies, and knowledge gaps related to SD during the COVID-19 pandemic.
3D Printed Models of Trochlear Dysplasia and Trochleoplasty Simulation for Trainee Education
Wentworth, Adam, Duit, Andrew, Yu, Kristin E. , Wentworth, Adam J, Morris, Jonathan M. , Hevesi, Mario

Arthroscopy Techniques | April 24, 2023 | Volume: 12 | Issue: 5 | Pages: No page available

10.1016/j.eats.2023.02.004 | PMID 37323795 Get It

Abstract Trochlear dysplasia is a major contributor to patellofemoral instability and subsequent failure of isolated soft tissue reconstruction procedures in the treatment of recurrent patellar dislocation and/or subluxation. Trochleoplasty procedures aim to address abnormal osseous trochlear morphologic factors that contribute to patellar maltracking. However, teaching these techniques is limited by the lack of reliable training models for trochlear dysplasia and trochleoplasty simulation. Although a cadaveric knee model of trochlear dysplasia for trochleoplasty simulation has been recently described, cadaveric knees are less amenable for use in trochleoplasty planning and surgeon training because of the absence of reliable, natural dysplastic anatomic relationships, such as suprapatellar spurs due to the rarity of dysplastic cadavers and the high cost of cadaveric specimens. Furthermore, readily available sawbone models represent “normal” osseous trochlear morphology and are difficult to modify and bend due to their material composition. Given this, we have developed a cost‐effective, reliable, and anatomically accurate three‐dimensional (3D) knee model of trochlear dysplasia for trochleoplasty simulation and trainee education. Technique Video video See video under supplementary data.
Age, Hypertension, and Exercise Capacity are Independently Associated with Likelihood of Multi-Vessel Disease in Patients Referred for Treadmill Exercise Testing: The Intermediate-High-Workload Treadmill Score (IHWTS)
Calle, Maria C. Arciniegas, Abbasi, Muhannad , Bello, Laura B. Garcia, Bonikowske, Amanda R. , Villarraga, Hector R. , Abbasi, Muhannad Aboud , Salah, Husam M, Salah, Husam M. , Scott, Christopher G.

Reviews in Cardiovascular Medicine | April 24, 2023 | Volume: 24 | Issue: 4 | Pages: No page available

10.31083/j.rcm2404108 | PMID 39076284 Get It

Background: To identify factors that increase the specificity of the treadmill exercise test (TMET), and develop a novel scoring system which accounts for functional capacity to aid in determining the need for further testing. Methods: We retrospectively evaluated the electronic health records of 600 patients who had positive TMET results and follow-up stress echocardiography from 1-January-2004, through 31-December-2016. Correlations between clinical and aerobic variables and multivessel disease (MVD) were determined. Duke Treadmill Score (DTS) was calculated and compared with a novel scoring system titled the Intermediate-High-Workload Treadmill Score (IHWTS) that used variables associated with MVD. Results: In total, 124 of 600 patients (21%) had coronary catheterization, and 51 of these patients (41%) had MVD. Mean (SD) DTS was –2.10 (6.3) among patients with MVD vs –0.16 (5) among patients without MVD (p = 0.06). Mean (SD) functional aerobic capacity (FAC) was 76% (20%) among patients with MVD vs 90% (21%) among patients without MVD (p < 0.001). Mean (SD) metabolic equivalent (MET) was 7 (2) among patients with MVD vs 8 (2) among patients without MVD (p = 0.002). Only 6 (12%) of patients with MVD achieved 9 MET or greater on TMET. DTS less than 4 did not distinguish between patients with and without MVD (p = 0.67). Age, hypertension and FAC were independently associated with MVD (all p < 0.05). Conclusions: Our novel scoring system IHWTS utilized age, hypertension, and FAC appeared comparable to DTS to risk-stratify patients regardless of baseline symptoms. Clinical parameters such as hypertension along with exercise functional capacity should be considered when evaluating a positive TMET result in patients that achieve an intermediate-high workload >5 Metabolic Equivalents (METs).
Efficacy of RestoreX after prostatectomy: open‐label phase of a randomized controlled trial
Zganjar, Andrew , Toussi, Amir , Ziegelmann, Matthew , Frank, Igor, Boorjian, Stephen A. , Tollefson, Matthew K. , Köhler, Tobias , Trost, Landon , Tollefson, Matthew

BJU International | April 23, 2023 | Volume: 132 | Issue: 2 | Pages: 217-226

10.1111/bju.16033 | PMID 37088866 Get It

Objective To report open‐label phase data from a recent randomized controlled trial (RCT), after previous data from that study showed improved penile length and erectile function among post‐prostatectomy men treated with Restorex penile traction therapy (RxPTT). Materials and Methods An RCT (NCT05244486) was performed to evaluate RxPTT vs no treatment (Tx) for 5 months, which was followed by a 3‐month open‐label phase. Men were stratified based on as‐treated data: Group 1 = No Tx; Group 2 = No Tx → Tx; Group 3 = Tx → No Tx; Group 4 = Tx. Assessments included stretched penile length and standardized (International Index of Erectile Function [IIEF]) and non‐standardized questionnaires. Results A total of 82 men were enrolled (mean age 58.6 years) with 9‐month data available in 45 of the men. Baseline characteristics were similar among the cohorts. Comparing Group 1 and Group 4 (respectively), notable differences included: IIEF Erectile Function domain (IIEF‐EF) score (−8 vs −0.5; P = 0.16), penile length (−0.1 vs +1.7 cm; P < 0.01), intracavernosal injection use (86% vs 14%; P < 0.01), Sexual Encounter Profile (SEP) Question 2 (50% vs 100%; P < 0.01), SEP Question 3 (33% vs 100%; P < 0.01). Men who crossed over to Tx (Group 2) failed to achieve equivalent improvements in length (+0.5 cm) or sexual function (IIEF‐EF score −6) compared to men treated early (Groups 3 and 4). Those who crossed over to no treatment after initial treatment (Group 3) experienced preserved length (+1.8 cm), and erectile function (IIEF‐EF score +0) despite therapy discontinuation. Conclusions Use of RxPTT beginning 1 month post‐prostatectomy results in improved penile length and erectile function, with benefits maintained after discontinuing therapy. If confirmed, these results represent the first postoperative therapy shown in a RCT to improve erectile function post‐prostatectomy. External validation is warranted.
Higher systolic blood pressure in early‐mid adulthood is associated with poorer cognitive performance in those with a dominantly inherited Alzheimer's disease mutation but not in non‐carriers. Results from the DIAN study
Xu, Ying , Aung, Htein Linn , Chhatwal, Jasmeer P. , Day, Gregory S. , Fagan, Anne M. , Farlow, Martin R. , Gordon, Brian A. , Kehoe, Patrick G. , Xiong, Chengjie , Mori, Hiroshi , Morris, John C. , Wharton, Whitney , Humburg, Peter , Peters, Ruth , (DIAN), Dominantly Inherited Alzheimer Network, Vöglein, Jonathan , Peters, Ruth , Gordon, Brian A , Day, Gregory S , Vöglein, Jonathan , Xiong, Chengjie , Morris, John C , Bateman, Randall J. , Brooks, William S. , Schofield, Peter R. , (DIAN), Dominantly Inherited Alzheimer Network

Alzheimer's & Dementia | April 23, 2023 | Volume: 19 | Issue: 11 | Pages: 4999-5009

10.1002/alz.13082 | PMID 37087693 Get It

AbstractBACKGROUNDThe Dominantly Inherited Alzheimer Network (DIAN) is a longitudinal observational study that collects data on cognition, blood pressure (BP), and other variables from autosomal‐dominant Alzheimer's disease mutation carriers (MCs) and non‐carrier (NC) family members in early to mid‐adulthood, providing a unique opportunity to evaluate BP and cognition relationships in these populations.METHODWe examined cross‐sectional and longitudinal relationships between systolic and diastolic BP and cognition in DIAN MC and NC.RESULTSData were available from 528 participants, who had a mean age of 38 (SD = 11) and were 42% male and 61% MCs, at a median follow‐up of 2 years. Linear‐multilevel models found only cross‐sectional associations in the MC group between higher systolic BP and poorer performance on language (β = −0.181 [−0.318, −0.044]), episodic memory (−0.212 [−0.375, −0.049]), and a composite cognitive measure (−0.146 [−0.276, −0.015]). In NCs, the relationship was cross‐sectional only and present for language alone.DISCUSSIONHigher systolic BP was cross‐sectionally but not longitudinally associated with poorer cognition, particularly in MCs. BP may influence cognition gradually, but further longitudinal research is needed.
Novel initiatives are always welcome
Jaffe, Allan S. , Jaffe, Allan S.

European Heart Journal: Acute Cardiovascular Care | April 22, 2023 | Volume: 12 | Issue: 6 | Pages: 372-373

10.1093/ehjacc/zuad044 | PMID 37086470 Get It

εγ-Thalassemia, a New Hemoglobinopathy Category
Oliveira, Jennifer L. , Thompson, Christineil , Saravanaperumal, Siva Arumugam , Koganti, Tejaswi , Jenkinson, Garrett , Hein, Molly S., Kohorst, Mira A. , Hasadsri, Linda , Nguyen, Phuong L., Matern, Dietrich , Kipp, Benjamin R. , Klee, Eric W. , Wieben, Eric D. , Hoyer, James D., Rangan, Aruna , Thompson, Christineil H

Clinical Chemistry | April 22, 2023 | Volume: 69 | Issue: 7 | Pages: 711-717

10.1093/clinchem/hvad038 | PMID 37086467 Get It

Abstract Background Large β-globin gene cluster deletions (hereditary persistence of fetal hemoglobin [Hb] or β-, δβ-, γδβ-, and ϵγδβ-thalassemia), are associated with widely disparate phenotypes, including variable degrees of microcytic anemia and Hb F levels. When present, increased Hb A2 is used as a surrogate marker for β-thalassemia. Notably, ϵγδβ-thalassemias lack the essential regulatory locus control region (LCR) and cause severe transient perinatal anemia but normal newborn screen (NBS) results and Hb A2 levels. Herein, we report a novel deletion of the ϵ, Aγ, Gγ, and ψβ loci with intact LCR, δ-, and β-regions in 2 women and newborn twins. Methods Capillary electrophoresis (CE), high-performance liquid chromatography (HPLC), DNA sequencing, multiplex ligation-dependent probe amplification (MLPA), gap-polymerase chain reaction (gap-PCR), and long-read sequencing (LRS) were performed. Results NBS showed an Hb A &gt; Hb F pattern for both twins. At 20 months, Hb A2 was increased similarly to that in the mother and an unrelated woman. Unexplained microcytosis was absent and the twins lacked severe neonatal anemia. MLPA, LRS, and gap-PCR confirmed a 32 599 base pair deletion of ϵ (HBE1) through ψβ (HBBP1) loci. Conclusions This deletion represents a hemoglobinopathy category with a distinct phenotype that has not been previously described, an ϵγ-thalassemia. Both the NBS Hb A &gt; F pattern and the subsequent increased Hb A2 without microcytosis are unusual. A similar deletion should be considered when this pattern is encountered and appropriate test methods selected for detection. Knowledge of the clinical impact of this new category will improve genetic counselling, with distinction from the severe transient anemia associated with ϵγδβ-thalassemia.